← Menopause guide

If you've been feeling "off" for months — irregular periods, disrupted sleep, brain fog, or a metabolism that seems to have changed overnight — you may be in perimenopause. And you're far from alone.

The menopausal transition is one of the most significant hormonal shifts a woman's body undergoes. Yet most women enter it without being told what to expect. This guide breaks it down clearly, using current clinical evidence, so you can recognize what's happening and have an informed conversation with your provider.

The three phases: fertility, perimenopause, and menopause

These three terms are often used interchangeably — but they describe distinct phases with different hormonal patterns and different clinical implications.

Phase 1
Reproductive years
Estrogen and progesterone cycle predictably each month. Overall hormone levels remain relatively stable.
Phase 2
Perimenopause
Hormone levels become erratic — estrogen surges and drops unpredictably while progesterone steadily declines. Typically lasts 4–10 years.
Phase 3
Menopause
Defined as 12 consecutive months without a menstrual period. Estrogen and progesterone settle at a persistently low level.
Clinical note

The average age of menopause in the U.S. is 51–52 years, but perimenopause commonly begins in the mid-to-late 40s — and for some women, as early as the late 30s. Early menopause (before age 45) and premature ovarian insufficiency (POI, before age 40) are distinct conditions that warrant prompt evaluation and management.[1,2]

What's happening to your hormones

The root cause of perimenopausal symptoms is a decline in ovarian function — specifically, a reduction in the number and quality of follicles available to produce estrogen and progesterone. This doesn't happen smoothly.

During perimenopause, estrogen levels fluctuate widely — sometimes spiking higher than reproductive-age norms before eventually declining. Progesterone tends to drop first and more consistently, as cycles become anovulatory. This imbalance drives many of the earliest symptoms: breast tenderness, heavy periods, and mood changes.[3]

By the time menopause is confirmed, both hormones have settled at chronically low levels. This sustained estrogen deficiency drives long-term health considerations including bone density loss, cardiovascular risk changes, and genitourinary atrophy.[4]

Why symptoms are so unpredictable

The erratic nature of estrogen during perimenopause explains why symptoms vary so much week to week. A period of significant hot flashes may be followed by relative calm. This reflects the actual hormonal fluctuation of this phase — not mood, willpower, or imagination. Progesterone's more linear decline is why irregular cycles and sleep disruption often appear early, even when estrogen levels are still relatively high.[3]

Recognizing perimenopausal symptoms

Perimenopause affects nearly every organ system. Understanding which systems are involved helps connect symptoms you may have attributed to stress, aging, or other causes.

Vasomotor
  • Hot flashes
  • Night sweats
  • Palpitations
  • Flushing
Psychological
  • Anxiety
  • Mood swings
  • Irritability
  • Depressive mood
  • Brain fog
  • Poor memory
  • Low libido
Sleep
  • Interrupted sleep
  • Difficulty falling asleep
  • Early waking
Menstrual changes
  • Shorter or longer cycles
  • Heavier or lighter flow
  • Spotting between periods
  • Skipped periods
Genitourinary
  • Vaginal dryness
  • Painful intercourse
  • Urinary urgency
  • Recurrent UTIs
Systemic
  • Joint soreness & stiffness
  • Weight changes
  • Skin thinning/dryness
  • Headaches
  • Back pain

Hot flashes and night sweats

Hot flashes — sudden waves of heat, often accompanied by flushing and sweating — are the hallmark of perimenopause and affect up to 75–80% of women during the transition.[5] They result from estrogen-related changes in the brain's thermoregulatory center in the hypothalamus, which becomes hypersensitive to small temperature fluctuations.

Night sweats are essentially hot flashes occurring during sleep. They are among the most common drivers of sleep disruption in perimenopausal women — and disrupted sleep, in turn, worsens appetite regulation, mood, and metabolic function. This is a cycle worth interrupting.

Duration of vasomotor symptoms

The SWAN (Study of Women's Health Across the Nation) cohort found that hot flashes persist for a median of 7.4 years across the menopause transition — and women who begin experiencing them earlier in perimenopause tend to have the longest duration. Vasomotor symptoms are not simply a brief transition that resolves quickly for most women.[6]

Mood changes and brain fog

Estrogen isn't only a reproductive hormone — it has extensive effects on brain function. Estrogen receptors are distributed throughout regions that regulate mood (limbic system), memory (hippocampus), and sleep (hypothalamus). The hormonal turbulence of perimenopause can contribute to anxiety, irritability, low mood, and cognitive changes that many women describe as "not feeling like themselves."

Brain fog — difficulty concentrating, word-finding problems, and memory lapses — is one of the most commonly reported but least-discussed perimenopausal symptoms. Research from the SWAN study and Penn Ovarian Aging Study confirms that objective cognitive performance can decline during the menopause transition, with most women showing recovery after menopause is established.[7]

Perimenopausal depression

Perimenopausal depression is a distinct clinical entity from major depressive disorder, though the two can co-occur. Women with a history of depression, PMS/PMDD, or postpartum mood disorders are at higher risk for significant mood symptoms during perimenopause. If mood symptoms are severe, persistent, or functionally impairing, they warrant clinical evaluation and treatment — not reassurance that "it's just hormones." Hormone therapy has demonstrated benefit for perimenopausal mood symptoms in randomized trials.[8] A 2018 JAMA Psychiatry RCT found transdermal estradiol with micronized progesterone significantly reduced depressive symptom incidence during the menopause transition.

Weight changes during the transition

One of the most frustrating aspects of perimenopause for many women is a shift in body composition — particularly an increase in abdominal fat — that can occur even without changes in diet or activity. This is not a willpower problem. It is biology.

The mechanisms are multiple and simultaneous: declining estrogen shifts fat distribution from peripheral (hips and thighs) to visceral (abdominal); disrupted sleep elevates cortisol and ghrelin; and muscle mass declines with age, reducing resting metabolic rate. Women in the menopause transition experience a decrease in total 24-hour energy expenditure of approximately 9% and a 30% drop in spontaneous physical activity energy expenditure.[9]

Metabolic implications of visceral fat

The visceral fat accumulation characteristic of the menopausal transition carries metabolic consequences beyond weight — it is directly associated with increased cardiovascular risk, insulin resistance, elevated inflammatory markers, and higher rates of type 2 diabetes. This is a central reason why metabolic health screening becomes particularly important during and after this life stage.[10]

When to seek help

Not every perimenopausal symptom requires medical intervention — but some do, and some require prompt attention. Here is a practical framework for knowing when to make an appointment.

Seek evaluation promptly for
  • Any bleeding after 12 consecutive months without a period — this requires evaluation to rule out endometrial pathology, including cancer
  • Heavy bleeding — soaking through a pad or tampon every hour, or passing clots larger than a quarter
  • Cycles less than 2 weeks apart, or bleeding lasting longer than 2 weeks
  • Symptoms severe enough to interfere with sleep, work, or relationships — effective treatments exist and are underutilized
  • New or worsening depression or anxiety not responding to usual coping strategies
  • Any thoughts of self-harm — seek care urgently via your provider, urgent care, or a crisis line (988)

Even if your symptoms feel manageable, a proactive conversation with your provider about where you are in the transition is worthwhile. Many women go years without being offered treatment options that could meaningfully improve their quality of life.

Treatment options: what the evidence supports

Effective treatments for perimenopausal and menopausal symptoms exist and are significantly underutilized. Treatment decisions should be individualized based on symptom severity, health history, and patient preference.

Menopausal hormone therapy (MHT)

Previously called hormone replacement therapy (HRT), MHT is the most effective treatment for vasomotor symptoms and genitourinary symptoms of menopause. Current evidence — including reanalysis of the Women's Health Initiative data and multiple subsequent trials — supports its use in healthy women under 60, or within 10 years of menopause onset, for symptom management.[11,12] The Menopause Society and ACOG both support individualized MHT decisions based on current evidence.

Non-hormonal options

For women who cannot or prefer not to use hormone therapy, evidence-based alternatives include: SSRIs and SNRIs (paroxetine, venlafaxine) for hot flashes and mood; gabapentin for vasomotor symptoms and sleep; and fezolinetant (Veozah), a neurokinin 3 receptor antagonist FDA-approved in 2023 specifically for moderate-to-severe vasomotor symptoms in women who cannot use hormones.[13,14]

Lifestyle and behavioral approaches

Lifestyle interventions do not replace medical treatment for severe symptoms but can meaningfully improve quality of life in the transition. Resistance training preserves muscle mass and bone density; a high-protein, plant-rich diet supports metabolic health and gut microbiome diversity; and cognitive behavioral therapy (CBT) has demonstrated efficacy for both sleep disruption and hot flash distress in randomized controlled trials.[15]

A note on supplements

The supplement market for menopause is enormous and largely unregulated. Products including black cohosh, phytoestrogens, and "adrenal support" blends are widely marketed but have limited and inconsistent evidence for symptom relief. Some carry potential drug interactions or contraindications in hormone-sensitive conditions. Always discuss supplements with your provider before starting them.[15]

Long-term health after menopause

The post-menopausal years bring shifts in long-term health risk that deserve proactive attention even after acute symptoms have resolved.

Bone density. Estrogen plays a critical role in maintaining bone. The years immediately following menopause are associated with the most rapid bone loss — up to 2–3% per year in early postmenopause. DEXA screening is recommended at age 65, or earlier in high-risk women. Calcium (1,200 mg/day total), vitamin D (800–1,000 IU/day), and resistance exercise are foundational supportive measures.[16]

Cardiovascular health. Prior to menopause, estrogen confers some degree of cardiovascular protection. After menopause, women's cardiovascular risk rises significantly and becomes comparable to men's by the mid-60s. Blood pressure, fasting lipids, and blood glucose warrant regular monitoring — and any new cardiovascular symptoms should be taken seriously.[17]

Cognitive health. The relationship between estrogen, timing of hormone therapy, and dementia risk remains an active area of research. The "critical window" hypothesis proposes that MHT initiated near the time of menopause may have different cognitive effects than initiation years later. Current evidence does not support initiating MHT solely for dementia prevention; ongoing trials are examining this directly.[18]

References

  1. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10 (STRAW+10). Menopause. 2012;19(4):387–395. doi:10.1097/gme.0b013e31824d8f40
  2. Webber L, Davies M, Anderson R, et al.; ESHRE Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. doi:10.1093/humrep/dew027
  3. Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021;106(1):1–15. doi:10.1210/clinem/dgaa764
  4. Peacock K, Ketvertis KM. Menopause. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 29262194. NBK507826
  5. Avis NE, Crawford SL, Greendale G, et al.; SWAN. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. doi:10.1001/jamainternmed.2014.8063
  6. Faubion SS, Enders F, Hedges MS, et al. Impact of menopause symptoms on women in the workplace. Mayo Clin Proc. 2023;98(6):833–845. doi:10.1016/j.mayocp.2023.02.025
  7. Greendale GA, Karlamangla AS, Maki PM. The menopause transition and cognition. JAMA. 2020;323(15):1495–1496. doi:10.1001/jama.2020.1757
  8. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–157. doi:10.1001/jamapsychiatry.2017.3998
  9. Kapoor E, Collazo-Clavell ML, Faubion SS. Weight gain in women at midlife: a concise review of the pathophysiology and strategies for management. Mayo Clin Proc. 2017;92(10):1552–1558. doi:10.1016/j.mayocp.2017.08.004
  10. Davis SR, Castelo-Branco C, Chedraui P, et al.; Writing Group of the International Menopause Society for World Menopause Day 2012. Understanding weight gain at menopause. Climacteric. 2012;15(5):419–429. doi:10.3109/13697137.2012.707385
  11. The Menopause Society. The 2023 Menopause Society position statement on hormone therapy. Menopause. 2023;30(6):573–590. doi:10.1097/GME.0000000000002200
  12. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810
  13. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–1102. doi:10.1016/S0140-6736(23)00085-5
  14. Johnson KA, Martin N, Nappi RE, et al. Efficacy of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause over 52 weeks. Obstet Gynecol. 2023;141(2):255–265. doi:10.1097/AOG.0000000000005048
  15. Pines A, Langer RD. Menopausal hormone therapy in 2023: understanding the past, present and future. Climacteric. 2023;26(2):107–112. doi:10.1080/13697137.2022.2151099
  16. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi:10.1210/jc.2019-00221
  17. El Khoudary SR, Aggarwal B, Beckie TM, et al.; American Heart Association Prevention Science Committee. Menopause transition and cardiovascular disease risk: implications for timing of early prevention. Circulation. 2020;142(25):e506–e532. doi:10.1161/CIR.0000000000000912
  18. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional's guide for decision-making and individualized treatment strategies. Climacteric. 2022;25(6):570–578. doi:10.1080/13697137.2022.2122792